NO965017D0 - Oligonukleotider med anti-cytomegalovirus aktivitet - Google Patents

Oligonukleotider med anti-cytomegalovirus aktivitet

Info

Publication number
NO965017D0
NO965017D0 NO965017A NO965017A NO965017D0 NO 965017 D0 NO965017 D0 NO 965017D0 NO 965017 A NO965017 A NO 965017A NO 965017 A NO965017 A NO 965017A NO 965017 D0 NO965017 D0 NO 965017D0
Authority
NO
Norway
Prior art keywords
oligonucleotides
cytomegalovirus
disclosed
cytomegalovirus activity
activity
Prior art date
Application number
NO965017A
Other languages
English (en)
Other versions
NO965017L (no
Inventor
Gregory S Pari
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of NO965017D0 publication Critical patent/NO965017D0/no
Publication of NO965017L publication Critical patent/NO965017L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO965017A 1994-05-25 1996-11-25 Oligonukleotider med anti-cytomegalovirus aktivitet NO965017L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/249,386 US5801235A (en) 1994-05-25 1994-05-25 Oligonucleotides with anti-cytomegalovirus activity
PCT/US1995/006160 WO1995032213A1 (en) 1994-05-25 1995-05-19 Oligonucleotides with anti-cytomegalovirus activity

Publications (2)

Publication Number Publication Date
NO965017D0 true NO965017D0 (no) 1996-11-25
NO965017L NO965017L (no) 1997-01-22

Family

ID=22943254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965017A NO965017L (no) 1994-05-25 1996-11-25 Oligonukleotider med anti-cytomegalovirus aktivitet

Country Status (11)

Country Link
US (1) US5801235A (no)
EP (1) EP0754188B1 (no)
JP (1) JPH10500851A (no)
KR (1) KR970703355A (no)
AT (1) ATE160354T1 (no)
AU (1) AU698089B2 (no)
CA (1) CA2191191A1 (no)
DE (1) DE69501081T2 (no)
ES (1) ES2112062T3 (no)
NO (1) NO965017L (no)
WO (1) WO1995032213A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153595A (en) * 1990-08-16 2000-11-28 Isis Pharmaceuticals Inc. Composition and method for treatment of CMV infections
AU2215097A (en) * 1996-03-14 1997-10-01 Hybridon, Inc. Selected oligonucleotides with anti-cytomegalovirus activity
WO1997048795A2 (en) * 1996-06-18 1997-12-24 Hybridon, Inc. Compositions and methods for treating specific gene expression-related diseases and disorders in humans
WO2004009027A2 (en) * 2002-07-19 2004-01-29 Myriad Genetics, Inc Method and composition for treating and preventing herpesvirus infection
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
EP0277773A1 (en) * 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Hybrid cytomegalovirus (CMV) and vaccine
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5149798A (en) * 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
DE68922102T2 (de) * 1989-10-13 1995-10-19 Phobos Nv Verfahren zur kontinuierlichen Herstellung von hochmolekularen Polyester-Harzen.
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
BR9106751A (pt) * 1990-08-16 1993-08-17 Isis Pharmaceuticals Ind Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
US5242906A (en) * 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
AU698089B2 (en) 1998-10-22
JPH10500851A (ja) 1998-01-27
EP0754188B1 (en) 1997-11-19
CA2191191A1 (en) 1995-11-30
WO1995032213A1 (en) 1995-11-30
EP0754188A1 (en) 1997-01-22
AU2591395A (en) 1995-12-18
NO965017L (no) 1997-01-22
ATE160354T1 (de) 1997-12-15
DE69501081D1 (de) 1998-01-02
DE69501081T2 (de) 1998-07-02
KR970703355A (ko) 1997-07-03
ES2112062T3 (es) 1998-03-16
US5801235A (en) 1998-09-01

Similar Documents

Publication Publication Date Title
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
CA2177732A1 (en) Antisense oligonucleotides having tumorigenicity-inhibiting activity
CA2089666A1 (en) Oligonucleotides for modulating the effects of cytomegalovirus infections
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
ATE128189T1 (de) Hybridizierungssonden von dem abstand zwischen den 16s und 23s rna genen und nachweis von nicht- viralen mikroorganismen.
CA2132424A1 (en) Antisense oligonucleotide inhibition of papillomavirus
WO2001002423A3 (en) 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith
DE60325016D1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
EP1100809A4 (en) 2'-MODIFIED OLIGONUCLEOTIDES WITH RNS EFFECT THAT ARE CONFORMALLY RESTRICTED
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
NO983716L (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
FI946201A0 (fi) Itsestabiloidut oligonukleotidit terapeuttisina aineina
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
NO965017L (no) Oligonukleotider med anti-cytomegalovirus aktivitet
FR2723950B1 (fr) Fragments nucleotidiques capables de s'hybrider specifiquemennt a l'adnr ou arnr des rickettsia et leur utilisation comme sondes ou amorces.
WO1996006949A3 (en) Nucleic acid hybridization assay probes targeted to mycoplasma pneumoniae nucleic acid
EP0503002A4 (en) Antisense oligonucleotide inhibition of papillomavirus
DE69732029D1 (de) Dna enthaltende impfstoffen
PT775745E (pt) Aptameros inibidores de catepsina g
WO1998009633A3 (en) Pharmaceutical compositions
IT1320168B1 (it) Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.
IL149640A0 (en) Antisense oligonucleotides
FR2721617B1 (fr) Fragments d'acides nucléiques, dérivés du génome de Mycobacterium xenopi et leurs applications.
TH28996B (th) "โอลิโกนิวคลีโอไทด์จำเพาะสำหรับไวรัสตับอักเสบ c
EP1724351A3 (en) Human Kallikrein-like genes